Market Cap 11.54M
Revenue (ttm) 1.63M
Net Income (ttm) -17.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,077.30%
Debt to Equity Ratio -0.04
Volume 936,194
Avg Vol 134,030
Day's Range N/A - N/A
Shares Out 1.65M
Stochastic %K 51%
Beta 2.15
Analysts Strong Sell
Price Target $16.50

Company Profile

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metast...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 9472 4101
Address:
Three International Towers, Level 24 300 Barangaroo Avenue, Sydney, Australia
BULLNATION_
BULLNATION_ Oct. 27 at 9:17 PM
$KZIA The reason @BULLNATION_ is here! Broke 8 and $9 now aiming for higher with newer momentum. Phase 3 FDA NEWS: "The FDA stated that overall survival is the "gold standard" endpoint in oncology and "should be prioritized as the primary endpoint when feasible" All technicals in place for a massive run! OUR PT $18-$22
0 · Reply
BULLNATION_
BULLNATION_ Oct. 27 at 9:13 PM
$KZIA Look at this SET UP! Management knows this is the perfect timing!
0 · Reply
BULLNATION_
BULLNATION_ Oct. 27 at 8:51 PM
$KZIA Almost no one shorting here, WHY? Because it is a BIG SHARK STOCK! Phase 3 is cooking and FDA has said GOLDEN STANDARD!
0 · Reply
BULLNATION_
BULLNATION_ Oct. 27 at 8:46 PM
$KZIA Still on the books TODAY! AH looking good!
0 · Reply
BULLNATION_
BULLNATION_ Oct. 27 at 8:45 PM
$KZIA This is right! Anyone loading up on this stage is going to be a millionaire if loading over 10k shares.
0 · Reply
jacckkmm
jacckkmm Oct. 27 at 8:02 PM
$KZIA hmmmm something smells good in AH
0 · Reply
dogood
dogood Oct. 27 at 6:20 PM
$KZIA every stock is green except thei and $CLRB
1 · Reply
LabMan
LabMan Oct. 27 at 5:44 PM
$KZIA The news from the company means if the FDA are agreeable - marketing of the drug can commence, in the short term. A brain cancer drug, for treatment of childrens DIPG was recently sold for $935 million. This drug called ONC201 had not been approved whatsoever by the FDA, at the time of the transaction. DIPG would only be a quarter of the market potential of GBM. Subsequently FDA did grant approval for selling of ONC201, pending a phase 3 study. A typical situation where accelerated approval is offered by the FDA. Once the drug is approved, it can be used for treatment of other types of cancers. re breast cancer, under off label conditions. Unknown to many investors, is the fact that 4O% of oncology drugs are sold, off label currently. This would be the intent of the company also, to get the drug into other areas, where studies and early trials are showing great success.
0 · Reply
TW_Research
TW_Research Oct. 27 at 5:22 PM
$KZIA looking for approval now is huge. Market doesn’t understand their PR I guess. Next batch of data will be positive if they are going to BLA. Cheapest biotech out there.
0 · Reply
dogood
dogood Oct. 27 at 3:41 PM
$KZIA all are flying , hope she gets to $9
0 · Reply
Latest News on KZIA
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Sep 12, 2024, 7:30 AM EDT - 1 year ago

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER


KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

Jan 18, 2024, 7:30 AM EST - 1 year ago

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS


KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

Nov 20, 2023, 4:30 PM EST - 2 years ago

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION


Kazia announces voluntary delisting from ASX

Oct 11, 2023, 7:01 AM EDT - 2 years ago

Kazia announces voluntary delisting from ASX


KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS

Jan 16, 2023, 7:01 AM EST - 3 years ago

KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS


BULLNATION_
BULLNATION_ Oct. 27 at 9:17 PM
$KZIA The reason @BULLNATION_ is here! Broke 8 and $9 now aiming for higher with newer momentum. Phase 3 FDA NEWS: "The FDA stated that overall survival is the "gold standard" endpoint in oncology and "should be prioritized as the primary endpoint when feasible" All technicals in place for a massive run! OUR PT $18-$22
0 · Reply
BULLNATION_
BULLNATION_ Oct. 27 at 9:13 PM
$KZIA Look at this SET UP! Management knows this is the perfect timing!
0 · Reply
BULLNATION_
BULLNATION_ Oct. 27 at 8:51 PM
$KZIA Almost no one shorting here, WHY? Because it is a BIG SHARK STOCK! Phase 3 is cooking and FDA has said GOLDEN STANDARD!
0 · Reply
BULLNATION_
BULLNATION_ Oct. 27 at 8:46 PM
$KZIA Still on the books TODAY! AH looking good!
0 · Reply
BULLNATION_
BULLNATION_ Oct. 27 at 8:45 PM
$KZIA This is right! Anyone loading up on this stage is going to be a millionaire if loading over 10k shares.
0 · Reply
jacckkmm
jacckkmm Oct. 27 at 8:02 PM
$KZIA hmmmm something smells good in AH
0 · Reply
dogood
dogood Oct. 27 at 6:20 PM
$KZIA every stock is green except thei and $CLRB
1 · Reply
LabMan
LabMan Oct. 27 at 5:44 PM
$KZIA The news from the company means if the FDA are agreeable - marketing of the drug can commence, in the short term. A brain cancer drug, for treatment of childrens DIPG was recently sold for $935 million. This drug called ONC201 had not been approved whatsoever by the FDA, at the time of the transaction. DIPG would only be a quarter of the market potential of GBM. Subsequently FDA did grant approval for selling of ONC201, pending a phase 3 study. A typical situation where accelerated approval is offered by the FDA. Once the drug is approved, it can be used for treatment of other types of cancers. re breast cancer, under off label conditions. Unknown to many investors, is the fact that 4O% of oncology drugs are sold, off label currently. This would be the intent of the company also, to get the drug into other areas, where studies and early trials are showing great success.
0 · Reply
TW_Research
TW_Research Oct. 27 at 5:22 PM
$KZIA looking for approval now is huge. Market doesn’t understand their PR I guess. Next batch of data will be positive if they are going to BLA. Cheapest biotech out there.
0 · Reply
dogood
dogood Oct. 27 at 3:41 PM
$KZIA all are flying , hope she gets to $9
0 · Reply
dogood
dogood Oct. 27 at 3:05 PM
$KZIA show us $9 and after hrs 2 digits
0 · Reply
BULLNATION_
BULLNATION_ Oct. 27 at 2:30 PM
$KZIA @BULLNATION_ is in the house and the pattern shows we will have VWAP broken today with a $11 test! Do not forget what we do here!
0 · Reply
dogood
dogood Oct. 27 at 2:09 PM
$KZIA let’s get to $10
0 · Reply
futureexmillionare
futureexmillionare Oct. 27 at 1:46 PM
$KZIA If they requested the meeting they probably have a partner lined up to do the phase 3 study. Thats my opinion.
0 · Reply
dogood
dogood Oct. 27 at 1:39 PM
$KZIA $12 to red , this is how this company trades
0 · Reply
BULLNATION_
BULLNATION_ Oct. 27 at 1:36 PM
$KZIA When people realize more about this, it will be too late! Loading up in early steps before $50+ https://www.prnewswire.com/news-releases/kazia-therapeutics-to-request-fda-type-c-meeting-to-discuss-overall-survival-data-in-gbm-and-potential-nda-filing-in-alignment-with-fda-initiative-project-frontrunner-302594782.html
0 · Reply
VMAESA
VMAESA Oct. 27 at 1:02 PM
So ya tellin’ me people actually pay attention to news, catalysts to make money in stock market? Lmao😂 If you only knew🤦‍♂️ $KZIA $RECT $ZBIO
0 · Reply
BULLNATION_
BULLNATION_ Oct. 27 at 1:00 PM
$KZIA Broke $9.37 resistance since $22 reach (9/11). Ready to go with ultra low volume. Last time she reached $22 it did with 1M volume. TODAY's VOLUME 736k She can be the stock of the day with some more volume, news itself is huge!
0 · Reply
gaboriar
gaboriar Oct. 27 at 12:51 PM
$KZIA volume
0 · Reply
dogood
dogood Oct. 27 at 12:50 PM
$CLRB both got extraordinarily and long waited news but hasn’t touched 2 digits , they have to cut lose to way higher lets open $KZIA
0 · Reply
BULLNATION_
BULLNATION_ Oct. 27 at 12:13 PM
$KZIA THIS IS NOT WORTH $22, THIS IS WORTH +$100 "FDA stated that overall survival is the "gold standard" endpoint in oncology and "should be prioritized as the primary endpoint when feasible,"
0 · Reply
dogood
dogood Oct. 27 at 12:04 PM
$KZIA once it crosses $12 today I will release my shares
0 · Reply